Literature DB >> 26609476

Three-dimensional assessment of bystander effects of mesenchymal stem cells carrying a cytosine deaminase gene on glioma cells.

Jin Hwa Jung1, Andrew Aujin Kim2, Da-Young Chang3, Yoo Ra Park4, Haeyoung Suh-Kim5, Sung-Soo Kim3.   

Abstract

Stem cells carrying a suicide gene have emerged as therapeutic candidates for their cytotoxic bystander effects on neighboring cancers, while being non-toxic to other parts of the body. However, traditional cytotoxicity assays are unable to adequately assess the therapeutic effects of bystander cells. Here, we report a method to assess bystander effects of therapeutic stem cells against 3-dimensionally grown glioma cells in real time. U87 glioma cells were stably transduced to express a green fluorescence protein and co-cultivated with mesenchymal stem cells engineered to carry a bacterial cytosine deaminase gene (MSC/CD). Following addition of a 5-fluorocytine (5-FC) prodrug to the co-culture, fluorescence from U87 cells was obtained and analyzed in real time. Notably, the IC50 of 5-FC was higher when U87 cells were grown 3-dimensionally in soft agar medium for 3 weeks, as compared to those grown for one week in two-dimensional monolayer cultures. Additionally, more MSC/CD cells were required to maintain a similar level of efficacy. Since three-dimensional growth of glioma cells under our co-culture condition mimics the long-term expansion of cancer cells in vivo, our method can extend to an in vitro assay system to assess stem cell-mediated anti-cancer effects before advancing into preclinical animal studies.

Entities:  

Keywords:  3D culture; Bystander effect; gene therapy; stem cell; suicide gene

Year:  2015        PMID: 26609476      PMCID: PMC4633898     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  21 in total

1.  The role of radio- and chemotherapy in glioblastoma.

Authors:  Roger Stupp; Damien C Weber
Journal:  Onkologie       Date:  2005-06-02

2.  Neural stem cell-based dual suicide gene delivery for metastatic brain tumors.

Authors:  C Wang; A Natsume; H J Lee; K Motomura; Y Nishimira; M Ohno; M Ito; S Kinjo; H Momota; K Iwami; F Ohka; T Wakabayashi; S U Kim
Journal:  Cancer Gene Ther       Date:  2012-09-28       Impact factor: 5.987

3.  A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference.

Authors:  Douglas A Rubinson; Christopher P Dillon; Adam V Kwiatkowski; Claudia Sievers; Lili Yang; Johnny Kopinja; Dina L Rooney; Mingdi Zhang; Melanie M Ihrig; Michael T McManus; Frank B Gertler; Martin L Scott; Luk Van Parijs
Journal:  Nat Genet       Date:  2003-02-18       Impact factor: 38.330

4.  Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.

Authors:  Roger Stupp; Michael Mayer; Roger Kann; Walter Weder; Abderahim Zouhair; Daniel C Betticher; Arnaud D Roth; Rolf A Stahel; Sabine Balmer Majno; Solange Peters; Lorenz Jost; Markus Furrer; Sandra Thierstein; Ralph A Schmid; Shu-Fang Hsu-Schmitz; René-Olivier Mirimanoff; Hans-Beat Ris; Miklos Pless
Journal:  Lancet Oncol       Date:  2009-07-13       Impact factor: 41.316

5.  Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.

Authors:  B E Huber; E A Austin; C A Richards; S T Davis; S S Good
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

6.  Dose translation from animal to human studies revisited.

Authors:  Shannon Reagan-Shaw; Minakshi Nihal; Nihal Ahmad
Journal:  FASEB J       Date:  2007-10-17       Impact factor: 5.191

7.  Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario.

Authors:  Cestmir Altaner; Veronika Altanerova; Marina Cihova; Katarina Ondicova; Boris Rychly; Ladislav Baciak; Boris Mravec
Journal:  Int J Cancer       Date:  2013-09-14       Impact factor: 7.396

8.  Strategies in gene therapy for glioblastoma.

Authors:  Aneta Kwiatkowska; Mohan S Nandhu; Prajna Behera; E Antonio Chiocca; Mariano S Viapiano
Journal:  Cancers (Basel)       Date:  2013-10-23       Impact factor: 6.639

9.  High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells.

Authors:  Vesa Hongisto; Sandra Jernström; Vidal Fey; John-Patrick Mpindi; Kristine Kleivi Sahlberg; Olli Kallioniemi; Merja Perälä
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

Review 10.  Bystander or no bystander for gene directed enzyme prodrug therapy.

Authors:  Gabi U Dachs; Michelle A Hunt; Sophie Syddall; Dean C Singleton; Adam V Patterson
Journal:  Molecules       Date:  2009-11-10       Impact factor: 4.411

View more
  7 in total

1.  Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review.

Authors:  Ioannis Christodoulou; Maria Goulielmaki; Marina Devetzi; Mihalis Panagiotidis; Georgios Koliakos; Vassilis Zoumpourlis
Journal:  Stem Cell Res Ther       Date:  2018-12-07       Impact factor: 6.832

2.  Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse.

Authors:  Adam Nowakowski; Katarzyna Drela; Justyna Rozycka; Miroslaw Janowski; Barbara Lukomska
Journal:  Stem Cells Dev       Date:  2016-09-07       Impact factor: 3.272

Review 3.  Recent progress in the research of suicide gene therapy for malignant glioma.

Authors:  Ryota Tamura; Hiroyuki Miyoshi; Kazunari Yoshida; Hideyuki Okano; Masahiro Toda
Journal:  Neurosurg Rev       Date:  2019-11-28       Impact factor: 3.042

Review 4.  Stem cells: a promising candidate to treat neurological disorders.

Authors:  Chang-Geng Song; Yi-Zhe Zhang; Hai-Ning Wu; Xiu-Li Cao; Chen-Jun Guo; Yong-Qiang Li; Min-Hua Zheng; Hua Han
Journal:  Neural Regen Res       Date:  2018-07       Impact factor: 5.135

Review 5.  Current status and potential challenges of mesenchymal stem cell-based therapy for malignant gliomas.

Authors:  Qing Zhang; Wei Xiang; Dong-Ye Yi; Bing-Zhou Xue; Wan-Wan Wen; Ahmed Abdelmaksoud; Nan-Xiang Xiong; Xiao-Bing Jiang; Hong-Yang Zhao; Peng Fu
Journal:  Stem Cell Res Ther       Date:  2018-08-24       Impact factor: 6.832

6.  A facile and scalable in production non-viral gene engineered mesenchymal stem cells for effective suppression of temozolomide-resistant (TMZR) glioblastoma growth.

Authors:  Geraldine Xue En Tu; Yoon Khei Ho; Zhi Xu Ng; Ke Jia Teo; Tseng Tsai Yeo; Heng-Phon Too
Journal:  Stem Cell Res Ther       Date:  2020-09-11       Impact factor: 6.832

7.  A highly efficient non-viral process for programming mesenchymal stem cells for gene directed enzyme prodrug cancer therapy.

Authors:  Yoon Khei Ho; Jun Yung Woo; Geraldine Xue En Tu; Lih-Wen Deng; Heng-Phon Too
Journal:  Sci Rep       Date:  2020-08-31       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.